PER — Percheron Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$10.87m
- AU$0.73m
- AU$0.37m
Annual income statement for Percheron Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | C2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.004 | 0.034 | 0.385 | 0.615 | 0.371 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 8.05 | 5.83 | 13.3 | 14.9 | 16.7 |
| Operating Profit | -8.05 | -5.8 | -13 | -14.3 | -16.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.06 | -5.81 | -11.4 | -11.9 | -14.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.06 | -5.81 | -11.4 | -11.9 | -14.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.06 | -5.81 | -11.4 | -11.9 | -14.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.06 | -5.81 | -11.4 | -11.9 | -14.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.015 | -0.009 | -0.017 | -0.014 | -0.015 |